Alvotech Partners With Advanz On European Eylea Biosimilar
Alliance On Both 2mg And 8mg Aflibercept Rivals Follows Several Deals And Guidance Raise
Alvotech has announced its latest European biosimilars partnership, collaborating with Advanz on both 2mg and 8mg aflibercept rivals to Eylea. The deal follows several other recent alliances as well as a raise in Alvotech’s full-year revenues guidance to as much as $500m.
